READING, United Kingdom – Friday, 25 May, 2012 – Quintiles has been named one of the top workplaces in the United Kingdom by the Great Place to Work Institute.  Placing fourth, the accolade follows awards in Germany, Ireland, Italy, and Spain in 2012.

The biopharmaceutical services firm scored highly for its sense of pride and camaraderie, with its efforts in corporate social responsibility, well-being and work-life balance rated above 2011 benchmarks.

This honour reflects our efforts to attract and develop talented individuals to help the biopharmaceutical industry increase research productivity, control costs and achieve greater returns on marketing and sales spending,” said Lindy Jones, Quintiles’ UK site head. “We are very proud to be recognised as a Great Place to Work for 2012 in multiple European markets.”

Tom O’Byrne, chief executive, Great Place to Work®, said: “This has been a particularly good year for the Best Workplaces list. I am delighted to congratulate all our winners on their achievement and thank their leaders for continuing to champion the importance of trust in the workplace. In the current economic climate, it has never been more crucial for organisations to recognise the importance of creating and maintaining great workplace cultures and the impact this can have on business performance.”

Every year Great Place to Work® surveys some 5,500 organisations around the world representing around 10 million employees. Best Workplace status is based on a Culture Audit and a Trust Survey of Employees. A Great Place to Work is one where employees "trust the people they work for, have pride in what they do, and enjoy the people they work with."

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit for more information and for additional company news.